If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Traditionally, homeless shelters ban alcohol. In 1997, as the result of an inquest into the deaths of two people experiencing homelessness who recreationally used alcohol two years earlier, Toronto's Seaton House became the first homeless shelter in Canada to operate a "wet shelter" on a "managed alcohol" principle in which clients are served a glass of wine once an hour unless staff determine that they are too inebriated to continue. Previously, people experiencing homelessness who consumed excessive amounts of alcohol opted to stay on the streets, often seeking alcohol from unsafe sources such as mouthwash, rubbing alcohol or industrial products which, in turn, resulted in frequent use of emergency medical facilities. The programme has been duplicated in other Canadian cities, and a study of Ottawa's "wet shelter" found that emergency room visit and police encounters by clients were cut by half. The study, published in the Canadian Medical Association Journal in 2006, found that serving people experiencing long-term homelessness and who consume excessive amounts of alcohol controlled doses of alcohol also reduced their overall alcohol consumption. Researchers found that programme participants cut their alcohol use from an average of 46 drinks a day when they entered the programme to an average of 8 drinks and that their visits to emergency rooms dropped from 13.5 to an average of 8 per month, while encounters with the police fall from 18.1 to an average of 8.8.
== Bibliography == Wergedahl, H; Liaset, B; Gudbrandsen, OA; Lied, E; Espe, M; Muna, Z; Mørk, S; Berge, RK (2004). "Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats". The Journal of Nutrition. 134 (6): 1320–7. doi:10.1093/jn/134.6.1320. PMID 15173391. Wu, Hui-Chun; Chen, Hua-Ming; Shiau, Chyuan-Yuan (2003). "Free amino acids and peptides as related to antioxidant properties in protein hydrolysates of mackerel (Scomber austriasicus)". Food Research International. 36 (9–10): 949–957. doi:10.1016/S0963-9969(03)00104-2. INIST 15251156. Marchbank, T.; Limdi, J. K.; Mahmood, A.; Elia, G.; Playford, R. J. (2008). "Clinical trial: Protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury". Alimentary Pharmacology & Therapeutics. 28 (6): 799–804. doi:10.1111/j.1365-2036.2008.03783.x. PMID 19145735. S2CID 31397. Nesse, Knut Olav; Nagalakshmi, A. P.; Marimuthu, P.; Singh, Mamta (2011). "Efficacy of a Fish Protein Hydrolysate in Malnourished Children". Indian Journal of Clinical Biochemistry. 26 (4): 360–5. doi:10.1007/s12291-011-0145-z. PMC 3210250. PMID 23024471. Kristinsson, Hordur G.; Rasco, Barbara A. (2000). "Fish Protein Hydrolysates: Production, Biochemical, and Functional Properties". Critical Reviews in Food Science and Nutrition. 40 (1): 43–81. doi:10.1080/10408690091189266. PMID 10674201. S2CID 28085824. Webb, K. E.; Bergman, E. N. (1991).
=== Role in Cardiovascular Events === The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-phosphodiesterase (PDE) pathway has become a target in developing treatments for heart failure. A deficit in cGMP levels has been associated with adverse cardiovascular outcomes, promoting factors like myocardial fibrosis, vasoconstriction, and inflammation, all of which accelerate heart failure progression. Some soluble guanylate cyclase (sGC) stimulators, have yielded promising outcomes in reducing cardiovascular events. Their effectiveness is thought to result from increased sensitivity of sGC to endogenous NO. Elevated plasma cGMP levels, regulated predominantly by natriuretic peptides (NP) rather than nitric oxide (NO), were found to correlate with a higher risk of heart failure, atherosclerotic cardiovascular disease, and coronary heart disease.
=== Administrative history === The ancient parish of Holyhead covered the majority of Holy Island. In 1832 a parliamentary borough was established covering just the area around the town itself, as a contributory borough to the Beaumaris Boroughs constituency. In 1860 a local government district was created covering the same area as the parliamentary borough, governed by an elected local board. Such local government districts were reconstituted as urban districts under the Local Government Act 1894. As part of the 1894 reforms, parishes were no long allowed to straddle district boundaries, and so the part of Holyhead parish outside the urban district became a separate parish called 'Holyhead Rural'. Holyhead Town Hall was completed in 1875 and served as both a public events venue and meeting place for the local board and the urban district council which replaced it. Holyhead Urban District was abolished in 1974, with its area instead becoming a community. District-level functions passed to Ynys Môn-Isle of Anglesey Borough Council, which in 1996 was reconstituted as a county council. The Holyhead Rural parish also became a community in 1974, and was renamed Trearddur in 1984.
Sources: en.wikipedia.org
Western Region (Vancouver, Seattle, San Francisco Bay Area, Los Angeles) Central Region (Guadalajara, Mexico City, Monterrey, Houston, Dallas, Kansas City) Eastern Region (Atlanta, Miami, Toronto, Boston, Philadelphia, New York/New Jersey) However, even during the group stage, about half of the teams had to play matches in two different regions.
If available, computed tomography (CT) is the most convenient tool in diagnosing NF due to its speed and resolution (detects about 80% of NF cases). CT scan may show fascial thickening, edema, or abscess formation. CT can pick up on gas within tissues better than MRI, but it is not unusual for NF to present without gas on imaging. In addition, CT helps evaluate complications due to NF and find possible sources of infections. Its use may be limited in pregnant patients and patients with kidney issues.
== Early life == Jones was born in Cincinnati, Ohio on May 17, 1893, to an Irish father and Black American mother. Little is known about his mother who left his life when Jones was a child. His father, John Jones, was a railroad worker who struggled to raise him on his own. Jones was raised by a Catholic priest, Father Ryan, at a rectory in Cincinnati, Ohio, near Covington. Father Ryan took in Jones around the age of seven, and two years later, John Jones died. Jones left school at age 11 after the sixth grade. He went to nearby Cincinnati, Ohio, working odd jobs including a role as a garage cleaning boy. By age 14, Jones was working as an automobile mechanic and was later named garage foreman. Jones was largely self taught.
Kazuaki Kiriya's action-thriller Last Knights was Freeman's first film of 2015, starring opposite Clive Owen. The plot centers on a band of warriors who seek to avenge the loss of their master at the hands of a corrupt minister. Reviews were largely underwhelming; Sara Stewart of New York Post called it "bloody bad", adding: "Once-proud box office names are its first casualties." Freeman next joined the cast of Ted 2, a comedy sequel to Ted, directed by Seth MacFarlane. The story follows the talking teddy bear Ted as he fights for civil rights in order to be recognized as a person. Freeman portrays Patrick Meighan, a highly respected civil rights attorney. A television series, Madam Secretary, also occupied Freeman's time. He played Chief Justice Frawley of the United States Supreme Court in a recurring role in the series. He and his producing partner Lori McCreary were executive producers. Freeman directed the first episode; McCreary remarked of his directing style, "What's riveting is that he can achieve a complete tonal change in performance with the least amount of direction ... Everybody behaves better when Morgan is there ... but he's very fun." At the end of 2015, Freeman played a U.S. senator in the thriller Momentum. Reprising his role as Allan Trumbull, Freeman appeared in London Has Fallen, the 2016 sequel to Olympus Has Fallen. The film follows a plot to assassinate the world leaders of the G7 as they attend the British Prime Minister's funeral in London, as well as Secret Service agent Mike Banning's efforts to protect U.S.
Glaxo Laboratories was incorporated as a distinct subsidiary company in London in 1935. Joseph Nathan's shareholders reorganised the group's structure in 1947, making Glaxo the parent and obtained a listing on the London Stock Exchange. Glaxo acquired Allen & Hanburys in 1958. The Scottish pharmacologist David Jack was hired as a researcher for Allen & Hanburys a few years after Glaxo took it over; he went on to lead the company's research and development (R&D) until 1987. After Glaxo bought Meyer Laboratories in 1978, it began to play an important role in the US market. In 1983, the American arm, Glaxo Inc., moved to Research Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North Carolina.
Sources: en.wikipedia.org
=== Accelerator mass spectrometry === HVEC tandems enabled accelerator mass spectrometry (AMS), a technique that transformed radiocarbon dating and created new applications across multiple fields. In May 1977, researchers at the University of Rochester used an HVEC MP tandem to demonstrate that carbon-14 atoms could be detected directly in milligram-scale samples—compared to the 10–100 grams required by conventional decay counting. The tandem configuration exploited a key property: nitrogen-14, the primary interference in conventional dating, forms no stable negative ions and cannot survive acceleration through the system, eliminating a major source of contamination. The reduction in sample size made radiocarbon dating applicable to precious artifacts and specimens where destructive sampling had been prohibitive. Tandem machines also extended the practical range of radiocarbon dating from approximately 40,000 to potentially 100,000 years. Beyond radiocarbon applications, AMS expanded into hydrology, geoscience, biomedicine, archaeology, and paleoclimatology.
ferredoxin–nicotinamide adenine dinucleotide reductase ferredoxin reductase NAD+-ferredoxin reductase ferredoxin–NAD+ reductase ferredoxin–linked NAD+ reductase ferredoxin–NAD reductase When NAD molecule is in its reduced form, the enzyme is referred to as:
Similarly, researchers from the Technical University of Munich and LMU Munich have developed a method to have T-cells target tumor cells by using antigen coated DNA origami. The researchers developed a method to create chassis known as programmable T-cell Engagers (PTEs) which are DNA origami structures that can be configured to bind to user-defined target cells and T-cells based on which antigens are coated on the surfaces of the nanostructure. The in vitro results show that after 24 hours of exposure 90% of the tumor cells were destroyed. Meanwhile, in vivo testing showed that their PTEs were capable of binding to the target proteins for several hours which validates the mechanism they designed.
=== Physical properties of NAPLs === The microscopic properties of NAPLs determine their behavior in the field. If they enter the saturated zone, their density relative to that of water will determine how they behave. As a result, NAPLs are categorized based on their relative density into two primary types: light non-aqueous phase liquids (LNAPLs) and dense non-aqueous phase liquids (DNAPLs). LNAPLs tend to float on the water table, while DNAPLs tend to sink downward and, in some conditions, pool at the bottom. Compared to LNAPLs, DNAPLs are more toxic and less biodegradable. There are a variety of parameters specific to the subsurface environment that are important to consider in quantitative models of NAPL behavior. Some of these parameters include soil permeability, moisture, particle size distribution, capillary force, wettability, and ground water flow velocity. The collection of this data is heterogeneous and complex in nature.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.